Clinical Trial Update: Long-Chain Fatty Acid Oxidation Disorders In-Clinic Disease Monitoring Program

View source ↗

Summary

The update indicates Ultragenyx's in-clinic disease monitoring program for long-chain fatty acid oxidation disorders is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Long-chain Fatty Acid Oxidation Disorders

Snippet

Sponsor: Ultragenyx Pharmaceutical Inc | Conditions: Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) | Status: ACTIVE_NOT_RECRUITING